BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $12,490 | $18,111 | $19,173 | $16,155 |
| - Cash | $943 | $755 | $725 | $587 |
| + Debt | $634 | $1,096 | $1,093 | $1,090 |
| Enterprise Value | $12,182 | $18,452 | $19,542 | $16,657 |
| Revenue | $2,854 | $2,419 | $2,096 | $1,846 |
| % Growth | 18% | 15.4% | 13.5% | – |
| Gross Profit | $2,274 | $1,887 | $1,593 | $1,376 |
| % Margin | 79.7% | 78% | 76% | 74.5% |
| EBITDA | $651 | $307 | $265 | $47 |
| % Margin | 22.8% | 12.7% | 12.7% | 2.6% |
| Net Income | $427 | $168 | $142 | -$64 |
| % Margin | 15% | 6.9% | 6.8% | -3.5% |
| EPS Diluted | 2.21 | 0.88 | 0.75 | -0.35 |
| % Growth | 151.1% | 17.3% | 314.3% | – |
| Operating Cash Flow | $573 | $159 | $176 | $305 |
| Capital Expenditures | -$97 | -$97 | -$121 | -$119 |
| Free Cash Flow | $475 | $63 | $55 | $185 |